amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte
Amorcyte Logo Cell Therapy Solutions for Cardiovascular Disease amorcyte home amorcyte contact us amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte
Amorcyte is currently engaged in a Phase 1 clinical trial for AMR-001 at three sites in the United States:

Emory University
Principal Investigator: Arshed A. Quyyumi, MD

The Texas Heart Institute
Co-Principal Investigators: Emerson C. Perin, MD, PhD; James T. Willerson, MD

Vanderbilt University School of Medicine
Douglas E. Vaughan, MD

AMR-001 is an autologous bone marrow derived CD 34 enriched cell product for the treatment of damaged heart muscle following Acute Myocardial Infarction (AMI).

amorcyte
amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte amorcyte
Back to Top
amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte